P. Cohen

发表

Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications

Daniel Birnbaum, Charles Theillet, Julie Vendrell, 2003, BMC Cancer.

mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels

I. Bièche, R. Lidereau, C. Dumontet, 2008, Cancer science.

Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling

B. Fervers, I. Treilleux, V. Maguer-Satta, 2016, Cell Death and Differentiation.

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

C. Collins, L. Payen, J. Vendrell, 2010, Molecular Cancer.

Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours

Alex Aussem, Sergio Rodrigues de Morais, Christian Gautier, 2013, Comput. Biol. Medicine.

Non-coding RNA in rhabdomyosarcoma progression and metastasis

P. Clézardin, N. Hussein, P. Cohen, 2022, Frontiers in Oncology.

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

B. Győrffy, P. Rouanet, J. Solassol, 2019, Front. Pharmacol..

The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression

M. Croset, P. Clézardin, N. Hussein, 2022, Cancers.

ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.

I. Bièche, R. Lidereau, C. Dumontet, 2008, Endocrine-related cancer.

ABCC 11 expression is regulated by estrogen in MCF 7 cells , correlated with estrogen receptor a expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells

I. Bièche, R. Lidereau, C. Dumontet, 2008 .

Environmental pollutants-dependent molecular pathways and carcinogenesis

P. Cohen, S. Ghayad, M. Diab‐Assaf, 2019, BioDiscovery.

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

H. Lincet, J. Vendrell, P. Cohen, 2015, Oncotarget.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer

C. Nguyen, I. Bièche, A. Thompson, 2008, Breast Cancer Research.

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

L. Meijer, M. Flajolet, P. Colas, 2013, Proceedings of the National Academy of Sciences.

Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.

C. Nguyen, D. Birnbaum, C. Theillet, 2004, Journal of molecular endocrinology.

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

I. Bièche, R. Lidereau, I. Treilleux, 2008, Journal of molecular endocrinology.

Identification of TACC 1 , NOV , and PTTG 1 as new candidate genes associated with endocrine therapy resistance in breast cancer

I. Bièche, R. Lidereau, I. Treilleux, 2009 .

Cracking the estrogen receptor's posttranslational code in breast tumors.

J. Renoir, L. Corbo, P. Cohen, 2011, Endocrine reviews.

A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells

C. Dumontet, J. Vendrell, N. Mechti, 2007, Oncogene.

ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.

I. Bièche, I. Treilleux, P. Roux, 2012, Cancer research.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

I. Bièche, C. Dumontet, J. Vendrell, 2010, International journal of cancer.

A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers

B. Győrffy, I. Bièche, I. Treilleux, 2014, Molecular oncology.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

T. Bachelot, J. Vendrell, L. Corbo, 2015, Breast Cancer Research.

Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.

A. di Pietro, C. Dumontet, Myléne Honorat, 2008, Biochemical and biophysical research communications.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

Thomas Bachelot, Florence Dalenc, Thomas Filleron, 2014, The Lancet. Oncology.

LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers.

J. van Rheenen, J. Coll, V. Josserand, 2016, Cancer research.

MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors

A. di Pietro, C. Dumontet, Myléne Honorat, 2011, International journal of breast cancer.

Biochemical characterization of different conformational states of the Sf9 cell‐purified p53His175 mutant protein

D. Lane, T. Hupp, P. Cohen, 1999, FEBS letters.

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer

B. Győrffy, J. Lachuer, J. Solassol, 2021, Frontiers in Oncology.

Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay

B. Győrffy, B. Fervers, J. Lachuer, 2020, Frontiers in Oncology.

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice

I. Treilleux, J. Coll, V. Josserand, 2019, Front. Pharmacol..

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone

B. Győrffy, I. Bièche, I. Treilleux, 2017, The Journal of pathology.

Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor

I. Treilleux, T. Bachelot, J. Vendrell, 2013, International journal of cancer.

Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.

C. Nguyen, I. Bièche, S. Tozlu, 2005, Endocrine-related cancer.

Steroid receptors and associated transcriptional cofactors in predicting the response to endocrine therapy

P. Cohen, S. Ghayad, 2008 .

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

I. Treilleux, T. Maudelonde, O. Trédan, 2015, Bulletin du cancer.

Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer

I. Treilleux, O. Trédan, J. Vendrell, 2019, International journal of molecular sciences.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

P. Cohen, S. Ghayad, Sandra E Ghayad, 2010, Recent patents on anti-cancer drug discovery.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

T. Bachelot, J. Vendrell, L. Corbo, 2015, Breast Cancer Research.

Elevated genetic variability in MCF-7 sublines and evidence of rapid genetic changes

C. Nguyen, D. Birnbaum, E. Douzery, 2002 .

Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).

I. Bièche, M. Mathieu, F. André, 2013 .

Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.

S. Vacher, I. Bièche, S. Tozlu, 2006, Endocrine-related cancer.

Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.

S. Vacher, I. Bièche, V. Lazar, 2007, Journal of molecular endocrinology.

Cracking the estrogen receptor's posttranslational code in breast tumors.

J. Renoir, L. Corbo, P. Cohen, 2011, Endocrine reviews.

LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers.

J. van Rheenen, J. Coll, V. Josserand, 2016, Cancer Research.

Intrabodies. Targeting scFv expression to eukaryotic intracellular compartments.

P. Cohen, P. Cohen, 2002, Methods in molecular biology.